Journal of Thoracic Oncology最新文献

{"title":"Touching (Proximity) as a Companion Diagnostic Test","authors":"Niki Gavrielatou MD , Parmees Fazeli , David L. Rimm MD, PhD","doi":"10.1016/j.jtho.2025.02.010","DOIUrl":"10.1016/j.jtho.2025.02.010","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 546-548"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Even With the CROWN Findings, There Remain Multiple First-Line Treatment Options for Patients With Advanced ALK–Positive NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 2 (2025) 150-153]","authors":"Vincent K. Lam MD , Shirish M. Gadgeel MD","doi":"10.1016/j.jtho.2025.02.006","DOIUrl":"10.1016/j.jtho.2025.02.006","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Page 680"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addendum to Lung Cancer in Austria https://doi.org/10.1016/j.jtho.2020.10.158 by R Pirker et al., J Thorac Oncol 2021, 16:725-733.","authors":"","doi":"10.1016/j.jtho.2023.10.011","DOIUrl":"10.1016/j.jtho.2023.10.011","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Page 681"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(25)00157-1","DOIUrl":"10.1016/S1556-0864(25)00157-1","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Page A3"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Further-Line Treatment With Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC: New Answers to Old Questions?","authors":"Sara Pilotto MD , Pawan Kumar Singh MD","doi":"10.1016/j.jtho.2025.02.012","DOIUrl":"10.1016/j.jtho.2025.02.012","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 549-554"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osimertinib and Performance Status 2: Not Every Patient Fits Into a Pivotal Clinical Trial","authors":"Ángel Artal-Cortes MD, PhD, Joaquín Gimeno-Pelegrín MD","doi":"10.1016/j.jtho.2025.02.011","DOIUrl":"10.1016/j.jtho.2025.02.011","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 557-559"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)","authors":"Francesco Passiglia PhD ,&nbsp;Angela Listì PhD ,&nbsp;Paolo Bironzo PhD ,&nbsp;Alessandra Merlini PhD ,&nbsp;Federica Benso BSc ,&nbsp;Francesca Napoli PhD ,&nbsp;Francesca Alice Barbu BSc ,&nbsp;Vanessa Zambelli BSc ,&nbsp;Fabrizio Tabbò PhD ,&nbsp;Maria Lucia Reale MD ,&nbsp;Claudio Sini MD ,&nbsp;Elisa Roca MD ,&nbsp;Paola Adriana Taveggia MD ,&nbsp;Francesca Simionato MD ,&nbsp;Lucio Buffoni MD ,&nbsp;Laura Mazilu MD ,&nbsp;Vito Barbieri PhD ,&nbsp;Daniele Pignataro MD ,&nbsp;Antonio Araujo PhD ,&nbsp;Luis Paz-Ares PhD ,&nbsp;Silvia Novello PhD","doi":"10.1016/j.jtho.2024.12.010","DOIUrl":"10.1016/j.jtho.2024.12.010","url":null,"abstract":"<div><h3>Introduction</h3><div>The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients’ access to clinical trials in Europe.</div></div><div><h3>Methods</h3><div>From January 2021 to December 2023, 20 centers located at five different European countries (Greece, Slovenia, Romania, Albania, and Italy) joined EPROPA, with 555 patients with advanced NSCLC registered to the program. Anonymized patients’ clinical-pathological data were shared through the EPROPA web platform and tissue samples were collected at the Molecular Pathology Unit of the Reference Center (University of Turin) for molecular analyses. A comprehensive genomic profiling by a targeted next-generation sequencing approach has been performed and molecular reports have been discussed within the molecular tumor board to assess patients’ eligibility for clinical trials.</div></div><div><h3>Results</h3><div>The average turnaround time was eight days, with only 30 out of 555 tissue samples (6%) not suitable for molecular analysis. In the 525 analyzed samples, a total of 570 molecular alterations have been identified, including 264 pathogenic targetable oncogenic alterations and 113 cases with co-occurring mutations. A total of 18 molecular alterations with potential germline and hereditary cancer syndrome implications have been reported. The identification of a clinical trial was considered for 205 patients. After molecular tumor board discussion, 30 patients were enrolled and treated in clinical studies available in Europe. Survival outcomes were significantly improved in patients with targetable molecular alterations receiving a matched targeted therapy.</div></div><div><h3>Conclusion</h3><div>This data confirmed the feasibility and usefulness of the program in the real-world practice scenario, supporting the implementation of next-generation sequencing–based molecular characterization of NSCLC samples, to reduce the unequal access to tests, drugs, and clinical trials in Europe.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 614-624"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting Announcements","authors":"","doi":"10.1016/S1556-0864(25)00159-5","DOIUrl":"10.1016/S1556-0864(25)00159-5","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Page A4"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study","authors":"So Yeon Kim MD ,&nbsp;Gerard A. Silvestri MD, MS ,&nbsp;Yeon Wook Kim MD, PhD ,&nbsp;Roger Y. Kim MD, MSCE ,&nbsp;Sang-Won Um MD, MPH, PhD ,&nbsp;Yunjoo Im MD ,&nbsp;Jung Hye Hwang MD ,&nbsp;Seung Ho Choi MD, PhD ,&nbsp;Jung Seop Eom MD, PhD ,&nbsp;Kang Mo Gu MD ,&nbsp;Yong-Soo Kwon MD, PhD ,&nbsp;Shin Yup Lee MD, PhD ,&nbsp;Hyun Woo Lee MD, PhD ,&nbsp;Dong Won Park MD, PhD ,&nbsp;Yeonjeong Heo MD ,&nbsp;Seung Hun Jang MD, PhD ,&nbsp;Kwang Yong Choi MD ,&nbsp;Yeol Kim MD, PhD ,&nbsp;Young Sik Park MD, PhD","doi":"10.1016/j.jtho.2024.12.006","DOIUrl":"10.1016/j.jtho.2024.12.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Guideline-discordant low-dose computed tomography (LDCT) screening may cause lung cancer (LC) overdiagnosis, but its extent and consequences are unclear. This study aimed to investigate the prevalence of self-initiated, non-reimbursed LDCT screening in a predominantly non-smoking population and its impact on LC epidemiology and healthcare utilization.</div></div><div><h3>Methods</h3><div>This nationwide cohort study analyzed data from Korea’s National Health Information Database and 11 academic hospital screening centers (1999–2022). The overall analysis encompassed the entire Korean population. For non-reimbursed LDCT screening prevalence, which the National Health Information Database does not capture, a separate analysis was conducted on a cohort of 1.7 million adults to extrapolate nationwide rates. Outcomes included trends in self-initiated, non-reimbursed LDCT screening, LC incidence, mortality, stage and age at diagnosis, 5-year survival, and LC-related healthcare utilization, including surgeries and biopsies. Joinpoint regression assessed trend changes.</div></div><div><h3>Results</h3><div>Self-initiated, non-reimbursed LDCT screening during health check-ups increased from 29% to 60% in men and 7% to 46% in women, despite only 2.4% of men and 0.04% of women qualifying for risk-based screening. In women, localized-stage LC incidence nearly doubled (age-standardized incidence rate: from 7.6 to 13.7 per 100,000), whereas distant-stage incidence decreased (age-standardized incidence rate: from 16.1 to 15.0 per 100,000). LC mortality declined (age-standardized mortality rate: from 23.3 to 19.8 per 100,000), whereas 5-year survival rates improved substantially. LC diagnoses in women shifted towards earlier stages and younger ages. Lung surgeries for both malignant and benign lesions, frequently lacking nonsurgical biopsies, increased sharply in women.</div></div><div><h3>Conclusions</h3><div>Widespread guideline-discordant LDCT screening correlates with LC overdiagnosis and increased healthcare utilization, particularly in women. Randomized controlled trials are needed to assess the risks and benefits of screening in low-risk populations to determine its efficacy and consequences.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 577-588"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials","authors":"Sebastien Gendarme MD ,&nbsp;Ehsan Irajizad PhD ,&nbsp;James P. Long PhD ,&nbsp;Johannes F. Fahrmann PhD ,&nbsp;Jennifer B. Dennison PhD ,&nbsp;Seyyed Mahmood Ghasemi PhD ,&nbsp;Rongzhang Dou MD, PhD ,&nbsp;Robert J. Volk PhD ,&nbsp;Rafael Meza PhD ,&nbsp;Iakovos Toumazis PhD ,&nbsp;Florence Canoui-Poitrine MD, PhD ,&nbsp;Samir M. Hanash MD, PhD ,&nbsp;Edwin J. Ostrin MD, PhD","doi":"10.1016/j.jtho.2025.01.003","DOIUrl":"10.1016/j.jtho.2025.01.003","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate how comorbidities affect mortality benefits of lung cancer screening (LCS) with low-dose computed tomography.</div></div><div><h3>Methods</h3><div>We developed a comorbidity index (Prostate, Lung, Colorectal, and Ovarian comorbidity index [PLCO-ci]) using LCS-eligible participants’ data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial (training set) and the National Lung Screening Trial (NLST) (validation set). PLCO-ci predicts five-year non–lung cancer (LC) mortality using a regularized Cox model; with performance evaluated using the area under the receiver operating characteristics curve. In NLST, LC mortality (per original publication) was compared between low-dose computed tomography and chest radiograph arms across the PLCO-ci quintile (Q1–5) using a cause-specific hazard ratio (csHR) with 95% confidence intervals (CIs).</div></div><div><h3>Results</h3><div>Analyses included 34,690 PLCO and 53,452 NLST participants (mean age: 62 y [±5 y] and 61 y [±5 y], 58% and 59% male individuals, and 39% and 41% active smokers, respectively). PLCO-ci predicted five-year non-LC mortality with an area under the receiver operating characteristics curve of 0.72 (95% CI: 0.71–0.74) in PLCO and 0.69 (95% CI: 0.67–0.70) in NLST. In NLST, at a median follow-up of 6.5 years, LC mortality was significantly reduced for participants with intermediate comorbidity (Q2, Q3, and Q4): csHR 0.62 (95% CI: 0.41–0.95), 0.68 (95% CI: 0.48–0.96), and 0.72 (95% CI: 0.54–0.96) respectively, with a nonstatistically significant reduction for Q1 (csHR = 0.72, 95% CI: 0.45–1.17) and no reduction for Q5 participants (csHR = 0.99, 95% CI: 0.79–1.23). Participants in Q2, Q3, and Q4 (60%) accounted for 89% of LC deaths averted among all NLST participants. Q1 participants had low LC incidence, whereas Q5 had higher localized LC lethality, more squamous cell carcinomas, and untreated LC.</div></div><div><h3>Conclusions</h3><div>The PLCO-ci developed in this work shows that individuals with intermediate comorbidity benefited the most from LCS, highlighting the need of addressing comorbidities to achieve LC mortality benefits.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 565-576"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}